Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCL2L1 overexpression
i
Other names:
BCL2L1, Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52, BCL2-like 1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
598
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2L1 overexpression
Diffuse Large B Cell Lymphoma
BCL2L1 overexpression
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
BCL2L1 overexpression
Acute Lymphocytic Leukemia
BCL2L1 overexpression
Acute Lymphocytic Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
BCL2L1 overexpression
Non Small Cell Lung Cancer
BCL2L1 overexpression
Non Small Cell Lung Cancer
osimertinib + APG-1252
Sensitive: C3 – Early Trials
osimertinib + APG-1252
Sensitive
:
C3
osimertinib + APG-1252
Sensitive: C3 – Early Trials
osimertinib + APG-1252
Sensitive
:
C3
BCL2L1 overexpression
Multiple Myeloma
BCL2L1 overexpression
Multiple Myeloma
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
BCL2L1 overexpression
Gastric Cancer
BCL2L1 overexpression
Gastric Cancer
APG-1252
Sensitive: D – Preclinical
APG-1252
Sensitive
:
D
APG-1252
Sensitive: D – Preclinical
APG-1252
Sensitive
:
D
BCL2L1 overexpression
Mantle Cell Lymphoma
BCL2L1 overexpression
Mantle Cell Lymphoma
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
venetoclax
Resistant: D – Preclinical
venetoclax
Resistant
:
D
BCL2L1 overexpression
Acute Myelogenous Leukemia
BCL2L1 overexpression
Acute Myelogenous Leukemia
venetoclax + AZD5991
Sensitive: D – Preclinical
venetoclax + AZD5991
Sensitive
:
D
venetoclax + AZD5991
Sensitive: D – Preclinical
venetoclax + AZD5991
Sensitive
:
D
BCL2L1 overexpression
Pancreatic Cancer
BCL2L1 overexpression
Pancreatic Cancer
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
ACR-368 + ABT 263
Sensitive: D – Preclinical
ACR-368 + ABT 263
Sensitive
:
D
BCL2L1 overexpression
Mantle Cell Lymphoma
BCL2L1 overexpression
Mantle Cell Lymphoma
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
BCL2L1 overexpression
Multiple Myeloma
BCL2L1 overexpression
Multiple Myeloma
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
BCL2L1 overexpression
Chronic Lymphocytic Leukemia
BCL2L1 overexpression
Chronic Lymphocytic Leukemia
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
venetoclax + trametinib
Resistant: D – Preclinical
venetoclax + trametinib
Resistant
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login